Adverse Events In both phase 2 trials, there were no major safety signals with retatrutide use [45, 46]
In my practice, I am seeing exactly this pattern, with patients reporting concerns about loose, less elastic-feeling skin on the body, not only the face, and asking increasingly specific questions about what can actually be done about it
Also, retatrutide isn't FDA-approved, while Ozempic and Mounjaro are, so "better" depends on whether you prioritize efficacy or regulatory approval and availability
Success depends on many factors, including weight history, metabolic risk, appetite, activity, nutrition, sleep, stress, medical conditions, and medication history
Use the retatrutide reconstitution chart and follow these critical handling practices: Sterile technique is non-negotiable
Novo Nordisk, the manufacturer of semaglutide now says all doses are "continuously shipped" to meet U.S